Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects

Priskorn, Morten; Larsen, Frank; Segonzac, A.; Moulin, Maryline

doi:10.1007/s002280050282

Cited by 24 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study cimetidine increased the AUC of racemic citalopram, given in multiple doses, by 43% [10]. Although a nonenantioselective analysis method Table 1 The effect of multiple dosing with cimetidine or omeprazole on the pharmacokinetics of single dose escitalopram in healthy subjects ( n = 16 for each study) was used, these results are consistent with those reported in the present study.…”

Section: Discussionsupporting

confidence: 90%

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

Malling

Poulsen

Søgaard

2005

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimsTo investigate the effects of co-administration of cimetidine or omeprazole on the pharmacokinetics of escitalopram. MethodsTwo randomized placebo-controlled crossover studies were carried out. Sixteen healthy subjects were administered placebo, or cimetidine (400 mg twice daily) for 5 days (study 1) or omeprazole (30 mg once daily) for 6 days (study 2). On day 4 (study 1) or day 5 (study 2), a single dose of escitalopram (20 mg) was administered. Blood samples were taken at predetermined times for the measurement of serum concentrations of escitalopram and its demethylated metabolite (S-DCT). Treatmentemergent adverse events were also monitored. ResultsCo-administration with cimetidine caused a moderate increase in the systemic exposure [AUC(0, • )] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t 1/2 from 23.7 to 29.0 h (5.24 h [3. 75,6.70]). Coadministration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, • ) (1.51 [1.39, 1.64]) and a small increase in t 1/2 from 26.5 to 34.8 h (8.3 h [6.44, 10.2]). There was no significant change in S-DCT AUC(0, • ) after coadministration of either cimetidine or omeprazole. Co-administration of cimetidine or omeprazole had no effect on the incidence of treatment-emergent adverse events. ConclusionsIn view of the good tolerability of escitalopram, the pharmacokinetic changes observed on co-administration with cimetidine or omeprazole are unlikely to be of clinical concern.

show abstract

Section: Discussionsupporting

confidence: 90%

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

Malling

Poulsen

Søgaard

2005

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In an earlier investigation, cimetidine, a known inhibitor of the carrier-mediated secretion of organic bases, 14 was shown to significantly decrease the CL R of DCT and DDCT but not of citalopram. 15 A further explanation to the enantiospecificity seen in citalopram pharmacokinetics could lie in distribution volume. However, the enantiomeric difference in V ss /F was slight (9 ± 18% lower for (−)-(R)-relative to (+)-(S)-citalopram) and statistically insignificant, and discordant with the observed enantiomeric differences in citalopram half-lives.…”

Section: Resultsmentioning

confidence: 98%

Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans

et al. 1997

View full text Add to dashboard Cite

“…At 1 1/2 h, participants were set up for the electroencephalography (EEG) recording. Commencement of testing occurred at 2 h post-drug administration to coincide with the peak pharmacokinetics of both citalopram and reboxetine (t max =2-4 h), as demonstrated in human (Dostert et al 1997;Edwards et al 1995;Noble and Benfield 1997) and animal (Hyttel 1994;Invernizzi et al 1992Invernizzi et al , 1997Page and Lucki 2002;Priskorn et al 1997;Sacchetti et al 1999) studies, as well as electrophysiological and behavioural effects of the drugs on emotion processing (Harmer et al 2004;Kemp et al 2004b). The testing session lasted 1 h, during which time participants had their EEG recorded whilst completing a computerised facial expression recognition task (described below).…”

Section: Methodsmentioning

confidence: 92%

Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study

et al. 2008

View full text Add to dashboard Cite

Citalopram and reboxetine have selective effects on the temporal course of emotional processing with evidence to suggest specific effects on emotion expression decoding of positive (happy) emotional facial stimuli as evidenced by changes in the attention-modulated N250 but not structural encoding. These findings provide physiological evidence that antidepressants may shift perceptual biases in emotional processing away from negative and towards positive stimuli.

show abstract

Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects

Cited by 24 publications

References 5 publications

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans

Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study

Contact Info

Product

Resources

About